Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
October 24, 2022 07:00 ET
|
Trevena, Inc.
OLINVYK study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects OLINVYK oral presentation was selected as...
Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference
September 07, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Second Quarter 2022 Results and Provides Business Update
August 11, 2022 07:00 ET
|
Trevena, Inc.
OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study Phase 1 study for TRV045, a novel S1P receptor...
Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022
August 08, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock
July 29, 2022 17:27 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena, Inc. Announces Registered Direct Offering of Preferred Stock
July 29, 2022 08:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update
July 28, 2022 07:00 ET
|
Trevena, Inc.
OLINVYK demonstrated statistically significant reduced impact on neurocognitive functioning vs IV morphine on primary endpoint Successfully negotiated OLINVYK contract with a large group purchasing...
Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care
June 14, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Participate at the JMP Securities Life Sciences Conference
June 10, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., June 10, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 16:05 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...